April 2026
M	T	W	T	F	S	S
	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Immune Thrombocytopenia Pipeline – Advancing Toward Durable Disease Control

Yashveer Bhardwaj/LinkedIn

Dec 21, 2025, 06:21

Immune Thrombocytopenia Pipeline – Advancing Toward Durable Disease Control

Yashveer Bhardwaj, Team Lead Manager at DelveInsight Business Research LLP, shared on LinkedIn:

“Immune Thrombocytopenia Pipeline: Advancing Toward Durable Disease Control

The ImmuneThrombocytopenia Pipeline is witnessing significant momentum as biopharmaceutical companies intensify efforts to deliver longer-lasting platelet control, improved safety, and reduced treatment burden for patients living with this chronic autoimmune disorder. At DelveInsight, our latest pipeline analysis highlights how late- and early-stage innovations are reshaping the ITP treatment landscape.

December 09, 2025 marked a major milestone as Novartis reported positive Phase III VAYHIT2 results evaluating ianalumab in combination with eltrombopag in patients with primary ITP previously treated with corticosteroids. The combination therapy achieved a 45% prolongation in disease control, measured by time to treatment failure (TTF)—a clinically meaningful endpoint reflecting sustained safe platelet levels. Notably, the median TTF reached 13.0 months, nearly 2.8 times longer than the 4.7 months observed with placebo plus eltrombopag, reinforcing the potential of targeted combination approaches in ITP management.
December 09, 2025, Incyte advanced the pipeline with a Phase 2A study evaluating tafasitamab in adult participants with primary autoimmune blood cell disorders, including ITP, focusing on both safety and efficacy in this complex patient population.
December 05, 2025, further strengthened Novartis’ leadership in ITP research with another study assessing two different doses of ianalumab versus placebo, administered alongside first-line corticosteroids, to maintain platelet counts ≥30 G/L in adults with primary ITP—addressing an important unmet need in early-line therapy durability.
December 04, 2025, Eli Lilly and Company announced progress with pirtobrutinib, an oral therapy under investigation in a Phase 1/2 study. The program aims to evaluate tolerability, pharmacokinetics, and safety in Phase 1, followed by a deeper assessment of efficacy and safety across multiple doses in Phase 2—highlighting the growing interest in oral, targeted options for ITP patients.
December 02, 2025, argenx initiated a long-term study evaluating efgartigimod IV in primary ITP, featuring a double-blinded treatment period followed by multiple open-label extensions, with patients remaining in the study for up to 138 weeks. This design underscores the industry’s focus on long-term disease control and real-world durability.

Explore how these developments are shaping the future of Immune Thrombocytopenia Treatment with DelveInsight’s in-depth pipeline intelligence.”

Stay updated with Hemostasis Today.